From NASDAQ: 2025-05-27 23:19:00

Teva Pharmaceutical Industries Ltd. received Fast Track designation from the FDA for TEV-53408, an anti-IL-15 antibody, for celiac disease treatment in individuals on a gluten-free diet. The drug is currently in Phase 2a trials for efficacy and safety in adults with celiac disease. Fast Track status expedites drug development for serious conditions. TEV-53408 aims to inhibit IL-15 activity to prevent intestinal damage and symptoms in celiac disease patients.



Read more at NASDAQ: Teva Gets FDA Fast Track Designation For Investigational Celiac Disease Drug TEV-53408